Clinical Trial Update: DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update reporting completion of DNX-2401 (Delta-24-RGD-4C) for recurrent malignant gliomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Malignant Glioma

Drugs mentioned

• DNX-2401 (Delta-24-RGD)

Snippet

Sponsor: DNAtrix, Inc. | Conditions: Brain Cancer, Central Nervous System Diseases | Phase 1 | Status: COMPLETED